GlassScriptPhysician profile
Billy R Walton
NPI 1710944699
$998.63
in general payments reported to CMS, 2019-2025
20 companies · $47.66 in 2025
The $47.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.18 · 2020: $214 · 2021: $290 · 2022: $211 · 2023: $170 · 2024: $34.13 · 2025: $47.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $170.69 | 2020-2021 | |
| Lilly USA, LLC | $121.14 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.41 | 2022-2023 | Synjardy, Jardiance |
| Novartis Pharmaceuticals Corporation | $64.58 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.13 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $57.79 | 2020-2024 | Farxiga |
| Idorsia Pharmaceuticals US INC | $57.69 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $57.36 | 2020-2021 | |
| Amgen INC. | $48.92 | 2021-2025 | Evenity |
| Pfizer INC. | $43.14 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.22 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $34.09 | 2019-2020 | |
| Abbott Laboratories | $33.81 | 2021-2022 | |
| Abbvie INC. | $29.44 | 2021-2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $23.01 | 2023 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.90 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.85 | 2019 | |
| Currax Pharmaceuticals LLC | $15.38 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.08 | 2021 | |
| Esperion Therapeutics, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Walton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.